Literature DB >> 23187790

The role of intraoperative radiation therapy in the management of recurrent and locally advanced gynecologic cancers.

Olivia W Foley1, J Alejandro Rauh-Hain, Marcela G del Carmen.   

Abstract

For patients with locally advanced primary or recurrent gynecologic cancers, prognosis is poor. Doses of external beam radiation therapy required to treat either gross or microscopic disease in patients previously irradiated or treated surgically exceed doses that are tolerated by normal anatomic structures. Intraoperative radiation therapy allows maximal tumor control achievable with radiation while minimizing radiation exposure of dose-limiting surrounding structures. Intraoperative radiation therapy is a unique treatment modality, allowing direct visualization of the target volume during a planned surgical procedure. Intraoperative radiation therapy has the potential to improve both long-term local control and overall survival especially in patients with para-aortic and/or pelvic sidewall recurrences.

Entities:  

Mesh:

Year:  2013        PMID: 23187790     DOI: 10.1097/IGC.0b013e318275232f

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  3 in total

1.  Multimodality treatment for multiple recurrences of cervical cancer after radiotherapy: a case report.

Authors:  Zishuang Wang; Xiaojun Ren; Zhongshan Liu; Yunfeng Li; Tiejun Wang
Journal:  Transl Cancer Res       Date:  2022-04       Impact factor: 0.496

2.  Feasibility and Safety of Intraoperative Radiotherapy with Low Energy X-ray Photon Therapy for Recurrent Gynecological Cancer: A Case Series.

Authors:  Hui-Hua Chen; Pei-Yu Hou; Wan-Hua Ting; Pei-Wei Shueng; Sheng-Mou Hsiao
Journal:  Life (Basel)       Date:  2022-05-05

3.  Outcome of patients with local recurrent gynecologic malignancies after resection combined with intraoperative electron radiation therapy (IOERT).

Authors:  Nathalie Arians; Robert Foerster; Joachim Rom; Matthias Uhl; Falk Roeder; Jürgen Debus; Katja Lindel
Journal:  Radiat Oncol       Date:  2016-03-18       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.